The objective of this Specialty Section (founded in 2007) is to promote exchange of information among academic, clinical and preclinical researchers in ocular toxicology. The Section provides a forum for the interaction of toxicologists and other professionals involved in ocular toxicity/toxicology studies. Exchange of information is promoted through annual business meetings, sponsorship of sessions/workshops for the annual meeting and liaisons with other professional organizations.

President: Mercedes Salvador-Silva, Alcon
Vice President: Brenda Smith, Allergan
VP-Elect: Kathleen Krenzer, Iuvo BioScience
Treasurer: Russell Eyre, Acucela
Communications: Marcus Terneus, Boehringer Ingelheim
Councilors: Vlad Bantseev, Genentech
Florence Loget, Genentech
Postdoctoral Representative: Kaushal Joshi, Research Institute for Fragrance Materials, Inc.
Graduate Student Representative: Vacant
Past-President: Chris Somps, Pfizer

Career Achievement Awards

- Dr. Chris Murphy, UC Davis (2015)
- Dr. Richard Dubielzig, UW-Madison (2016)

Goals

- To serve as the focal point for interaction of members of the Society of Toxicology interested in Ocular Toxicology.
- To develop, propose, and conduct programs and educational activities that emphasize the latest developments in Ocular Toxicology.
- To relate those developments to the activities of the Society of Toxicology and to stimulate new growth in Ocular Toxicology as it relates to the science of toxicology.
- To share information with other professional organizations related to Ocular Toxicology.
- To act as a resource to the Society in the area of the Section’s interest.
- To advocate the development of sound science-based guidelines for ocular assessment of therapeutics and update, as needed, guidelines for ocular irritancy assessment.
- To organize educational programs which emphasize new developments and issues in ocular toxicology.

Future Directions for the Assessment of Ocular Toxicology

Advances in technology
Use of technologies such as next-generation imaging techniques to assess the morphology and function of the retina.

New therapies for ocular diseases
Increased use of biopharmaceuticals and the assessment of effects in the eye. Development of novel therapeutics such as drug/device combinations, and cell and gene therapy.

New ocular disease models
New models are currently being developed that mimic such diseases as Dry AMD.

Membership (99)

- Academic
- Industry
- Government
- Consultants
- Postdocs
- Students